Hardman & Co Q&A on Shield Therapeutics...

Hardman & Co Research Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital 23-Jan-2023 / 11:15 GMT/BST     Analyst interview  |  Life Sciences Q&A on Shield Therapeutics (STX)  |  Positioned for profitability with Viatris deal and its additional capitaltive   Shield Therapeutics (STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews. Martin summarises a number of announcements made by the company recently, explains Accrufer has performed in the US, a co-promotion deal with Viatris, changes made to the forecast and with the share price languishing what Martin expects to happen from here. Shield Therapeutics plc is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead medicine ACCRUFeR. Listen to the interview here If you are interested in meeting the company, you can register your interest here To contact us: Hardman & Co 1 Frederick's Place London EC2R 8AE www.hardmanandco.com Follow us on Twitter @HardmanandCo Analyst: Martin Hall [phone] [e-mail]   Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report. Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

1541257 23-Jan-2023